The primary objective of this study for the safety run-in cohorts of the study is to evaluate
the safety, tolerability, and recommended Phase 2 dose (RP2D) of magrolimab in combination
with nab-paclitaxel or paclitaxel (Safety Run-In Cohort 1), and sacituzumab govitecan (Safety
Run-In Cohort 2) in metastatic triple-negative breast cancer (mTNBC).
The primary objective of this study for Phase 2 Cohort 1 is to compare the efficacy of
magrolimab in combination with nab-paclitaxel or paclitaxel versus nab-paclitaxel or
paclitaxel alone, as determined by progression-free survival (PFS) by investigator
assessment.
The primary objective of this study for Phase 2 Cohort 2 is to evaluate the efficacy of
magrolimab in combination with sacituzumab govitecan as determined by confirmed objective
response rate (ORR) by investigator assessment.

Study to Evaluate the Safety and Efficacy of Magrolimab Combination Therapy in Adults With Unresectable, Locally Advanced or Metastatic Triple-Negative Breast Cancer

Fresno

Women's Cancer Care

Magrolimab

Nab-Paclitaxel

Paclitaxel

Sacituzumab govitecan

A Phase 2 Study of Magrolimab Combination Therapy in Patients With Unresectable, Locally Advanced or Metastatic Triple-Negative Breast Cancer

This phase III trial studies how well atezolizumab added to the usual radiation therapy works
in treating patients with stage I-IIA non-small cell lung cancer. Immunotherapy with
monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the
cancer, and may interfere with the ability of tumor cells to grow and spread. Radiation
therapy, such as stereotactic body radiation therapy, uses special equipment to position a
patient and deliver radiation to tumors with high precision. This method can kill tumor cells
with fewer doses over a shorter period and cause less damage to normal tissue. Giving
atezolizumab and radiation therapy may work better than radiation therapy alone in treating
patients with early non-small cell lung cancer.

Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer

Kaiser Permanente-Fresno

Atezolizumab

Biospecimen Collection

Quality-of-Life Assessment

Questionnaire Administration

Stereotactic Body Radiation Therapy

A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC

This ALCHEMIST trial studies genetic testing in screening patients with stage IB-IIIA
non-small cell lung cancer that has been or will be removed by surgery. Studying the genes in
a patient's tumor cells may help doctors select the best treatment for patients that have
certain genetic changes.

Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

Carboplatin

Cisplatin

Clinical Observation

Crizotinib

Cytology Specimen Collection Procedure

Erlotinib

Gemcitabine Hydrochloride

Nivolumab

Pembrolizumab

Pemetrexed

Pemetrexed Disodium

Placebo Administration

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

This study will investigate the effect of tirzepatide on the reduction of morbidity and
mortality in adults living with obesity and provide additional evidence for the potential
clinical benefits of tirzepatide in this population.

A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

Valley Research

Tirzepatide

Placebo

A Phase 3, Randomized, Double-blind, Placebo-Controlled Study to Investigate the Effect of Tirzepatide on the Reduction of Morbidity and Mortality in Adults With Obesity

The purpose of this study is to test the long-term safety of rimegepant in the acute
treatment of moderate or severe migraine in children and adolescents (≥ 6 to < 18 years of
age).

Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine

Neuro Pain Medical Center

Rimegepant / BHV3000

Phase 3, Multicenter, Open-label Study to Assess the Long-term Safety and Tolerability of Rimegepant for the Acute Treatment of Migraine (With or Without Aura) in Children and Adolescents ≥ 6 to <18 Years of Age.

The purpose of this study is to test the safety and efficacy of BHV-3000 versus placebo in
the acute treatment of moderate or severe migraine in children and adolescents.

Randomized Study in Children and Adolescents With Migraine: Acute Treatment

Rimegepant/BHV3000

Matching placebo

Phase 3, Multicenter, Randomized, Double-blind,Group Sequential, Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant or the Treatment of Migraine (With or Without Aura) in Children and Adolescents ≥ 6 to <18 Years of Age

The purpose of the study is to assess the safety and tolerability of UCB0599 and to
demonstrate the superiority of UCB0599 over placebo with regard to clinical symptoms of
disease progression over 12 and 18 months in participants diagnosed with early-stage
Parkinson's Disease.

A 18-month Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Oral UCB0599 in Study Participants With Early-stage Parkinson's Disease

Pd0053 50385

UCB0599

A Double-Blind, Placebo-Controlled, Randomized, 18-Month Phase 2a Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Oral UCB0599 in Study Participants With Early Parkinson's Disease

The main purpose of this study is to measure the safety and efficacy of LY3209590 compared
with insulin degludec in participants with type 1 diabetes treated with multiple daily
injection therapy.

A Study of LY3209590 Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy

LY3209590

Insulin Degludec

A Phase 3, Multicenter, Randomized, Parallel-Design, Open-Label Study to Evaluate the Efficacy and Safety of LY3209590 as a Weekly Basal Insulin Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy

The purpose of this study is to evaluate the efficacy of guselkumab treatment versus placebo
in skin of color participants with predominant moderate-to-severe body psoriasis or
predominant moderate-to-severe scalp psoriasis by assessing improvements in the signs and
symptoms of psoriasis.

Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/or Scalp Psoriasis

Community Regional Medical Center

Guselkumab

A Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of Guselkumab for the Treatment of Participants With Skin of Color Who Have Moderate-to-Severe Plaque Psoriasis and/or Moderate-to-Severe Scalp Psoriasis

Migraine is a common neurological disorder typically characterized by attacks of throbbing,
moderate to severe headache, often associated with nausea, vomiting, and sensitivity to light
and sound. Migraine is extremely common and disabling in children. The purpose of this study
is to evaluate how safe and effective ubrogepant is in the acute treatment of migraine in
children and adolescents.
Ubrogepant is a drug approved for the acute treatment of migraine in adults. Children and
adolescents (aged 6-17 years) with a history of migraine will be enrolled. The study will
include 2 cohorts of participants - PK Cohort and Main Study (non-PK cohort). Participants
aged 6-11 years in the PK Cohort will receive Dose A or Dose B of Ubrogepant for PK analysis
to determine dose selection for the main study. In the main study, after dose selection,
children aged 6-11 years will be randomized to receive either low or high dose of Ubrogepant
or placebo. There is a 1 in 3 chance that a participant will be assigned to placebo.
Adolescents aged 12-17 years will be randomized to receive either low or high dose of
Ubrogepant or placebo with a 1 in 3 chance of placebo assignment.
For qualifying migraine attacks, participants will receive oral tablets of the double-blind
study intervention. There will be an option to take a second dose of double-blind study
intervention (identical to initial dose), or rescue medication, 2 to 24 hours after the
initial dose, for headache of moderate/severe intensity. Around 1059 participants will be
enrolled in the study in approximately 120 sites in the United States. The study duration
will be up to 6 months.
There may be higher treatment burden for participants in this trial compared to their
standard of care. Participants will attend regular visits during the study at a hospital or
clinic. The effect of the treatment will be checked by medical assessments, blood tests,
checking for side effects and completing questionnaires.

Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)

Neuro Pain Medical Center /ID# 227966

Ubrogepant

Placebo-Matching Ubrogepant

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Single-attack Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Oral Ubrogepant in the Acute Treatment of Migraine With or Without Aura in Children and Adolescents (Ages 6-17)

Fresno, California

Fresno

< 0 mi

Study to Evaluate the Safety and Efficacy of Magrolimab Combination Therapy in Adults With Unresectable, Locally Advanced or Metastatic Triple-Negative Breast Cancer

< 0 mi

Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer

< 0 mi

Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

< 0 mi

A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

< 0 mi

Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine

< 0 mi

Randomized Study in Children and Adolescents With Migraine: Acute Treatment

< 0 mi

A 18-month Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Oral UCB0599 in Study Participants With Early-stage Parkinson's Disease

< 0 mi

A Study of LY3209590 Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy

< 0 mi

Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/or Scalp Psoriasis

< 0 mi

Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)